Final count confirms Active Biotech's new share issue oversubscribed


The 745,651 B shares subscribed without the support of subscription rights, corresponding to 3.32 percent of the total number of shares offered, will be allocated to those who have subscribed for such shares in accordance with the principles outlined in the prospectus.
The new share issue increases the number of B shares in Active Biotech by 22,492,584 and the share capital by SEK 224,925,840. Following the new share issue, total share capital amounts to SEK 337,388,760 and the number of shares to 33,738,876, of which 1,145,024 are A shares and 32,593,852 are B shares.
Active Biotech's new share issue will be completed according to the following timetable:
Notification of any allocation of shares not supported by subscription rights
Approximately May 26
Payment for shares allocated through subscription not supported by subscription rights
Approximately May 28
First day of trading in new B shares
Approximately June 4
Lund, May 23, 2003
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information about Active Biotech visit
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50